➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Johnson and Johnson
Medtronic
Express Scripts
McKesson

Last Updated: October 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,265,099

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,265,099 protect, and when does it expire?

Patent 7,265,099 protects BRIDION and is included in one NDA.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 7,265,099
Title:Use of chemical chelators as reversal agents for drug-induced neuromuscular block
Abstract: The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having general formula (A) wherein R is (a), (b) or (c); or general formula (B) wherein X is (a), (b) or (d), or a pharmaceutically acceptable salt thereof.
Inventor(s): Bom; Antonius Helena Adolf (Midlothian, GB), Muir; Alan William (Lanark, GB), Rees; David (Gothenburg, SE)
Assignee: Organon N.V. (Oss, NL)
Application Number:10/049,393
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,265,099

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No   Start Trial   Start Trial REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE   Start Trial
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes   Start Trial   Start Trial REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,265,099

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99306411Aug 13, 1999
PCT Information
PCT FiledAugust 07, 2000PCT Application Number:PCT/EP00/07694
PCT Publication Date:February 22, 2001PCT Publication Number: WO01/12202

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
AstraZeneca
McKinsey
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.